Étiquette : Dermatology

PORSOLT

by jbertholdin Institutions, Service Providers & others

PORSOLT

About the company

Porsolt, a long established, AAALAC accredited and fully GLP compliant, preclinical CRO, has been providing efficacy evaluation and safety pharmacology services for over 40 years, covering the drug development process from early screening through regulatory submission.

About the solution

Porsolt provides discovery and preclinical services (safety & efficacy) including in vitro assays, pathophysiological models in multiple species and cell lines, customized procedures, and tailored solutions. They offer to support drug development using high throughput screening, high content analysis, and high content histology platforms, drug formulation analysis, and bioanalytical services.

Their vast expertise covers the following areas: psychiatric and neurological disorders, cardiac and vascular diseases, oncology, pain, inflammation, gastrointestinal disorders, liver diseases, metabolic and eating disorders, respiratory diseases, dermatology, medical devices, and predictive toxicity of compounds.

Website
Key information

–  Therapeutic areas: Cardiovascular System, Central Nervious System,Dermatology,Gastrointestinal System,Histoilogy, Inflammation, Liver & Hepatic System,Medical Devices,Obesity & Metabolic Disorders, Oncology,Pain, Pharmacokinetics, Predictive Toxicity, Respiratory System, Safety Regulatory Package, Thrombosis/ Blood, Urogenital System,Biomarkers Assays, Cell & Tissue Banks,Formulation Analysis, Image Processing & Data Analysis,Technical Skills,Technical Capabilities.

–  Based in: Le Genest Saint Isle (FRANCE)

–  Employees: 51 – 200

–  Created in: 1940

ERBC GROUP

by jbertholdin Institutions, Service Providers & others

ERBC GROUP

About the company

ERBC is a leading preclinical CRO specializing in safety assessment—including safety pharmacology, genetic toxicology, in-vitro and in-silico toxicology, general toxicology, juvenile and reproductive & developmental toxicology—along with pharmacokinetics, bio-analytics, and translational research. Committed to scientific excellence and regulatory compliance, ERBC partners with pharmaceutical, biotech, chemical, and medical device companies to de-risk their development programs and advance human health.

About the solution

At ERBC Group, they strategize your approach to make your drug development a success:
– Build on most relevant translational models
– Select best predictive biomarkers
– Choose state-of-the-art technologies.

Their innovation includes AVI-PDX models.

Website
Key information

–  Main industry type: CRO/CDMO

–  Therapeutic areas: All therapeutic areas

–  Based in: Baugy (France)

–  Employees: 201-500

–  Created in: 1973

ETAP-LAB

by jbertholdin Institutions, Service Providers & others

ETAP-LAB

About the company

ETAP-Lab is a preclinical CRO renowned for its expertise in the fields of dermatology, neurology, cardiology and gastroenterology. It assesses the effectiveness of drug candidates and medical devices.

Founded in 1991, ETAP-Lab has now worked with 150 companies ranging from small biotechs to large pharmaceutical groups, both in France and further afield. Ever since the company’s earliest days, ETAP-Lab models have consistently offered high translational value associated with relevant protocols. Mainly comprised of scientific experts, our team analyses client requirements, offering guidance and advice in the development of a tailor-made solution.

ETAP-Lab studies are conducted to exacting quality standards, ensuring the reproducibility, transparency and traceability of tests while maintaining responsiveness and offering regular dialogue with our project managers.

About the solution

ETAP-Lab can fast-track your pipeline with preclinical excellence having high predictability level through in vitro and in vivo testing and rodent behavioural analysis:

– DERMATOLOGY: Wide portfolio of original inflammatory (psoriasis, atopic dermatitis) and wound-healing in vivo models.

– CARDIOLOGY: In-depth in vivo studies of major cardiovascular diseases like Pulmonary Arterial Hypertension, Ischemia Reperfusion, and Heart failures.

– NEUROLOGY: Original and translational in vivo and in vitro models of Stroke and neurodegenerative diseases like Alzheimer’s and Parkinson’s models.

– GASTROENTEROLOGY: In vivo models of gastrointestinal disorders like irritable bowel syndrome (IBS) and traveler’s diarrhea. Expertise in metabolic disturbances such as diabetes, obesity, and malnutrition.

Website
Key information

– Therapeutic areas: Dermatology, Neurology, Cardiology, Gastroenterology, Metabolism

– Based in: Production sites in France

– Employees: 11 – 50

– Created in: 1991

HTL BIOTECHNOLOGY

by jbertholdin Biotech, Pharma

HTL BIOTECHNOLOGY

About the company

HTL Biotechnology is a French biotech company and world leader in the development and responsible bioproduction of pharmaceutical-grade biopolymers. These biopolymers are used by healthcare companies for the development of treatments in a wide range of leading therapeutic areas such as ophthalmology, dermatology, medical aesthetics, and rheumatology.

For over 30 years, HTL Biotechnology has been a driving force for innovation in the sector, collaborating with research entities and biotech companies to address tomorrow’s medical needs (regenerative medicine, drug delivery, etc.).

Historically based in France, the company combines production, innovation, R&D and quality activities on its site. To meet the world’s growing need for biopolymers, the company has a subsidiary in Asia. HTL has been expanding in several countries, in particular to the US, where HTL is building a production facility and has a R&D lab.
HTL Biotechnology employs nearly 300 people worldwide.

About the solution

Biopolymers are at the heart of today’s and tomorrow’s therapeutic innovations, HTL Biotechnology offers:

Their current portfolio includes: hyaluronic acid and polynuleotides pharma-grade, sodium DNA cosmetic-grade

Their development portfolio includes : collagen (rhCOL3), heparosan, functionalized hyaluronic acid

Website
Key information

–  Main industry type: Biotech

–  Therapeutic areas: Ophthalmology, Medical Aesthetics, Rheumatology, Regenerative Medicine

–  Based in: Javené (France) ; R&D Lab in New Jersey (US)

–  Employees: 201 – 500

– Created in: 1992

QIMA LIFE SCIENCES

by jbertholdin Institutions, Service Providers & others

QIMA LIFE SCIENCES

About the company

QIMA Life Sciences brings together QIMA Bioalternatives, Newtone Technologies, and Monasterium Laboratory. The companies provide innovative testing and research solutions ranging from in silico screening to clinical imaging, as well as in vitro and ex vivo assays and non-invasive clinical sample bioanalysis. They also offer the exclusive “Blood assay solutions” for fresh whole blood testing.

They contribute to the development of testing methods as an alternative to animal experimentation, by offering solutions dedicated to preclinical research and to the development of drug candidates and to cosmetic active ingredients and formulations.

About the solution

The company provides a 360° offer with innovative testing and research solutions ranging from in silico screening to clinical imaging, as well as in vitro and ex vivo assays and non-invasive clinical sample bioanalysis.

Website
Key information

–  Therapeutic areas: Dermatology, Oncology, immunology, Neurobiology

–  Based in: Gençay (FRANCE)

–  Employees: 51 – 200

– Created in: 1996

ATLANTIC BONE SCREEN

by jbertholdin Biotech, Pharma

ATLANTIC BONE SCREEN

About the company

Atlantic Bone Screen is a French CRO providing non-GLP preclinical services.
Atlantic Bone Screen has a strong know-how in the field of osteoarticular indications / bone and joint diseases / biomaterials : inflammation & oncology & dermatology.
Atlantic Bone Screen has developed in vitro tests, in vivo animal models and benefits from robust and state-of-the-art platforms for 2D and 3D imaging, histology and histopathology.
Atlantic Bone Screen supports biotech and pharma companies to identify and characterize the therapeutic potential of their drug candidates, nutraceuticals and biomaterials through validated models and customized preclinical studies.

About the solution

Their specific expertise in bone physiology and bone diseases, cartilage and inflammatory diseases, and cancer models sets them apart from other global CROs.

Based on their internal experts and scientific network, they address their customers’ questions regarding their candidates and support them in screening, characterization, and validation of their leads to generate strong data for advancing through regulatory stages.

Additionally, their flexibility in customizing study designs, readouts, and communication and providing comprehensive reports throughout projects is highlighted as a real strength by their partners (96% of customers were either satisfied or very satisfied in the 2023 satisfaction survey).

Website
Key information

–  Therapeutic areas: Oncology, Bone Diseases, Osteoarticular Diseases, Inflammation, Dermatology, Cosmetics, Biomaterials.

–  Based in: Nantes

–  Employees: 11 – 50

– Created in: 2005